Four States Drop GLP-1 Obesity Coverage as Federal Expansion Model Launches

Key Takeaways:

• Four states eliminated Medicaid GLP-1 obesity coverage on January 1, 2026, reducing coverage from 16 to 13 states
• Budget pressures drove the cuts, with Pennsylvania alone projecting $380 million in savings through 2027
• The federal BALANCE model launched simultaneously to expand access, creating a complex patchwork of coverage

While the federal government moves to expand GLP-1 access through new programs, a growing number of states are pulling back coverage for financial reasons — creating a tale of two policy directions that's leaving millions caught in the middle.

Four states (California, New Hampshire, Pennsylvania, and South Carolina) have eliminated coverage of GLP-1s for obesity treatment, likely reflecting recent state budget challenges and the significant costs associated with coverage, according to new data from the Kaiser Family Foundation. The cuts took effect January 1, 2026, reducing the total number of states covering GLP-1 medications for weight management from 16 to 13.

The Budget Reality Behind State Cuts

The numbers behind these decisions are staggering. Pennsylvania spent $223 million on GLP-1 prescriptions for diabetes treatment for Medicaid recipients in 2022, the year before they were approved for weight-loss. Two years later, in 2024, prescriptions cost the state $650 million, and were projected to double this year.

DHS provided cost estimates from the policy shift, projecting the state will save about $380 million from now through the end of the next fiscal year. These aren't small adjustments — they're massive budget decisions driven by exponential growth in utilization.

California's Medi-Cal program took perhaps the most comprehensive approach to the cuts. Effective January 1, 2026, Medi-Cal will discontinue coverage of GLP-1 medications when prescribed for weight loss or weight-related indications for members age 21 and older. The state's Department of Health Care Services made clear this wasn't negotiable: The policy as of January 1, 2026, is that GLP-1 drugs used for weight loss or weight loss-related indications will no longer be covered. Claims submitted for these drugs will deny with Reject Code 70 – Product/Service Not Covered.

The financial pressure extends beyond individual states. When you consider that medications like semaglutide and tirzepatide can cost $800-$1,200 per month without insurance, the budget impact multiplies quickly as more people gain access.

Federal Expansion Meets State Contraction

The timing creates a striking contradiction. As these states were cutting coverage, the Trump administration was announcing the BALANCE (Better Approaches to Lifestyle and Nutrition for Comprehensive hEalth) Model designed to expand GLP-1 access through Medicare and Medicaid.

As part of this voluntary model, CMS will negotiate drug pricing and coverage terms with manufacturers of GLP-1 medications on behalf of state Medicaid agencies and Medicare Part D plan sponsors. The model is expected to launch in May 2026 for Medicaid and January 2027 for Medicare Part D.

But here's the catch: participation is entirely voluntary. Participation will be voluntary for manufacturers, states, and plans. This means states facing budget pressures may opt out entirely, while others might see the federal support as an opportunity to restore coverage.

The federal government recognizes the scope of potential demand. If Medicare covered anti-obesity medications more broadly, roughly 30 million beneficiaries would be eligible for treatment each year from 2026 to 2034, according to the Congressional Budget Office. That level of coverage expansion would represent a fundamental shift in how we approach obesity treatment nationally.

The Human Impact of Policy Whiplash

For people who were receiving coverage, the changes created immediate disruption. In California, existing patients had some protections, but the transition wasn't smooth. All previously approved PAs for these drugs will expire on December 31, 2025, meaning people had to scramble for alternatives or pay out of pocket starting January 1.

Since 2023, the state has paid for Medicaid patients' weight-loss treatment with these drugs, known as GLP-1s. The planned change, which takes effect Jan. 1, will mean they won't be covered solely for weight loss and obesity. That's thousands of people who built treatment plans around coverage that vanished overnight.

The political tension is palpable. State Rep. Arvind Venkat (D., Allegheny), also an active emergency physician, told Spotlight PA: "We say that we want to prevent severe illness, and unfortunately this is an example where we are restricting access in a way that will likely lead to more severe illness and less health and well-being among our fellow Pennsylvanians."

For many people, these policy changes mean having to choose between continuing effective treatment and managing other essential expenses. The sudden loss of coverage can disrupt not only weight management progress but also improvements in related conditions like diabetes and cardiovascular health.

A Patchwork System Emerges

What we're seeing is the emergence of a complex patchwork where your zip code increasingly determines your access to these medications. A few other states are planning or considering obesity drug restrictions in state fiscal year 2026 or 2027, and state interest in expanding coverage of obesity drugs is also waning according to this year's survey, with states continuing to report cost as the key factor contributing to obesity drug coverage decisions. The state obesity drug coverage landscape will continue to evolve as states respond to the recent announcement of the BALANCE model.

Even within states that maintain coverage, access isn't guaranteed. When covered, GLP-1s are typically subject to utilization controls such as prior authorization, which can further limit access. This means you might live in a state with official coverage but still face months-long approval processes or strict eligibility requirements.

The disparity creates a two-tiered system where your insurance coverage and geographic location can determine whether you have access to treatments that could significantly impact your health outcomes.

What This Means for You

If you're currently on a GLP-1 for weight management or considering starting treatment, your state's Medicaid policy is now the most important factor in determining your access and costs. The federal BALANCE model offers hope for expanded coverage, but it won't help immediately if your state has already cut coverage or chooses not to participate.

Your best strategy is to understand all your options. If you live in one of the 13 states still offering Medicaid coverage, you may want to compare costs across different programs to ensure you're getting the best deal. For those in states that have cut coverage, exploring telehealth providers or manufacturer direct-pay programs may be your most affordable path forward.

Consider working with specialized GLP-1 clinics that understand the evolving coverage landscape and can help you navigate insurance challenges. Many offer payment plans or can connect you with patient assistance programs when insurance falls short.

The landscape is changing rapidly, and having multiple options gives you the flexibility to adapt as policies shift. Whether through state Medicaid, the federal BALANCE model when it launches, or alternative payment methods, you still have ways to access these treatments — you need to know where to look and who can help you navigate the system.